Skip to main content
SpringerLink
Log in

From the magic bullet to an effective therapy: the peptide experience

  • Editorial Commentary
  • Published:
European Journal of Nuclear Medicine and Molecular Imaging Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Helisch A, Forster GJ, Reber H, Buchholz HG, Arnold R, Goke B, et al. Pre-therapeutic dosimetry and biodistribution of 86Y-DOTA-Phe1-Tyr3-octreotide versus 111In-pentetreotide in patients with advanced neuroendocrine tumours. Eur J Nucl Med Mol Imaging 2004. DOI 10.1007/s00259-004-1561-6.

  2. Reubi JC. Peptide receptors as molecular targets for cancer diagnosis and therapy. Endocr Rev 2003;24(4):389–427.

    Article  CAS  PubMed  Google Scholar 

  3. Wild D, Schmitt JS, Ginj M, Macke HR, Bernard BF, Krenning E, et al. DOTA-NOC, a high-affinity ligand of somatostatin receptor subtypes 2, 3 and 5 for labelling with various radiometals. Eur J Nucl Med Mol Imaging 2003;30(10):1338–47.

    Article  CAS  PubMed  Google Scholar 

  4. Reubi JC, Eisenwiener KP, Rink H, Waser B, Macke HR. A new peptidic somatostatin agonist with high affinity to all five somatostatin receptors. Eur J Pharmacol 2002;456(1–3):45–9.

    Article  CAS  PubMed  Google Scholar 

  5. Reubi JC, Korner M, Waser B, Mazzucchelli L, Guillou L. High expression of peptide receptors as a novel target in gastrointestinal stromal tumours. Eur J Nucl Med Mol Imaging 2004;31:803–10.

    Google Scholar 

  6. Mansi L, Panza N, Battista C, Pacilio G, Salvatore M. The biological approach to radioimmunoscintigraphy. Biomed Pharmacother 1990;44(6):295–301.

    Article  CAS  PubMed  Google Scholar 

  7. Pastore V, Di Lieto E, Mansi L, Rambaldi PF, Santini M, Mancusi R. Intraoperative detection of lung cancer by octreotide labeled to indium-111. Semin Surg Oncol 1998;15:220–2.

    Article  CAS  PubMed  Google Scholar 

  8. Mansi L, Rambaldi PF, Bizzarro A, Panza N, Di Martino S, De Bellis A, Del Vecchio E. Indium-111 octreotide in Graves’ disease and in the evaluation of active exophthalmos. Q J Nucl Med 1995;39:105–10.

    CAS  PubMed  Google Scholar 

  9. Rolleman EJ, Valkema R, de Jong M, Kooij PP, Krenning EP. Safe and effective inhibition of renal uptake of radiolabelled octreotide by a combination of lysine and arginine. Eur J Nucl Med Mol Imaging 2003;30(1):9–15.

    Article  CAS  PubMed  Google Scholar 

  10. Bodei L, Cremonesi M, Grana C, Rocca P, Bartolomei M, Chinol M, Paganelli G. Receptor radionuclide therapy with 90Y-[DOTA]0-Tyr3-octreotide (90Y-DOTATOC) in neuroendocrine tumours. Eur J Nucl Med Mol Imaging 2004;31(7):1038–46.

    Google Scholar 

  11. Kowalski J, Henze M, Schuhmacher J, Macke HR, Hofmann M, Haberkorn U. Evaluation of positron emission tomography imaging using [68Ga]-DOTA-D Phe1-Tyr3-octreotide in comparison to [111In]-DTPAOC SPECT. First results in patients with neuroendocrine tumors. Mol Imaging Biol 2003;5(1):42–8.

    Article  PubMed  Google Scholar 

  12. Hofmann M, Maecke H, Borner R, Weckesser E, Schoffski P, Oei L, et al. Biokinetics and imaging with the somatostatin receptor PET radioligand 68Ga-DOTATOC: preliminary data. Eur J Nucl Med 2001;28(12):1751–7.

    Article  CAS  PubMed  Google Scholar 

  13. Jamar F, Barone R, Mathieu I, Walrand S, Labar D, Carlier P, et al. 86Y-DOTA0-d-Phe1-Tyr3-octreotide (SMT487)—a phase 1 clinical study: pharmacokinetics, biodistribution and renal protective effect of different regimens of amino acid co-infusion. Eur J Nucl Med Mol Imaging 2003;30(4):510–8.

    CAS  PubMed  Google Scholar 

  14. Lubberink M, Tolmachev V, Widstrom C, Bruskin A, Lundqvist H, Westlin JE. 110mIn-DTPA-d-Phe1-octreotide for imaging of neuroendocrine tumors with PET. J Nucl Med 2002;43(10):1391–7.

    CAS  PubMed  Google Scholar 

  15. Forrer F, Uusijarvi H, Waldherr C, Cremonesi M, Bernhardt P, Mueller-Brand J, Maecke HR. A comparison of 111In-DOTATOC and 111In-DOTATATE: biodistribution and dosimetry in the same patients with metastatic neuroendocrine tumours. Eur J Nucl Med Mol Imaging 2004. DOI 10.1007/s00259-004-1553-6.

  16. Gabriel M, Decristoforo C, Maina T, Nock B, von Guggenberg E, Cordopatis P, Moncayo R. 99mTc-N4-[Tyr3]octreotate versus 99mTc-EDDA/HYNIC-[Tyr3]octreotide: an intrapatient comparison of two novel technetium-99m labeled tracers for somatostatin receptor scintigraphy. Cancer Biother Radiopharm. 2004;19(1):73–9.

    Article  CAS  PubMed  Google Scholar 

  17. Wester HJ, Schottelius M, Scheidhauer K, Meisetschlager G, Herz M, Rau FC, et al. PET imaging of somatostatin receptors: design, synthesis and preclinical evaluation of a novel 18F-labelled, carbohydrated analogue of octreotide. Eur J Nucl Med Mol Imaging 2003;30(1):117–22.

    Article  CAS  PubMed  Google Scholar 

  18. Froidevaux S, Eberle AN, Christe M, Sumanovski L, Heppeler A, Schmitt JS, et al. Neuroendocrine tumor targeting: study of novel gallium-labeled somatostatin radiopeptides in a rat pancreatic tumor model. Int J Cancer 2002;98(6):930–7.

    Article  CAS  PubMed  Google Scholar 

  19. de Jong M, Bakker WH, Krenning EP, Breeman WA, van der Pluijm ME, Bernard BF, et al. Yttrium-90 and indium-111 labelling, receptor binding and biodistribution of [DOTA0,d-Phe1,Tyr3]octreotide, a promising somatostatin analogue for radionuclide therapy. Eur J Nucl Med 1997;24(4):368–71.

    Article  PubMed  Google Scholar 

  20. Kwekkeboom DJ, Bakker WH, Kooij PP, Konijnenberg MW, Srinivasan A, Erion JL, et al. [177Lu-DOTA0Tyr3]octreotate: comparison with [111In-DTPA0]octreotide in patients. Eur J Nucl Med 2001;28(9):1319–25.

    Article  CAS  PubMed  Google Scholar 

  21. Reubi JC, Schar JC, Waser B, Wenger S, Heppeler A, Schmitt JS, Macke HR. Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur J Nucl Med 2000;27(3):273–82.

    Article  CAS  PubMed  Google Scholar 

  22. Erion J, Schmidt T, Wilhelm R, Achilefu S, Srinavasan A. Biodistribution and radiotherapy studies using samarium-153 and lutetium-177 DTPA conjugates of Y3-Octreotate. J Nucl Med 1999;40 (Suppl):223P.

    Google Scholar 

  23. De Jong M, Valkema R, Jamar F, Kvols LK, Kwekkeboom DJ, Breeman WA, et al. Somatostatin receptor-targeted radionuclide therapy of tumors: preclinical and clinical findings. Semin Nucl Med. 2002;32(2):133–40.

    Article  PubMed  Google Scholar 

  24. de Jong M, Breeman WA, Bernard BF, Bakker WH, Schaar M, van Gameren A, et al. [177Lu-DOTA0,Tyr3] octreotate for somatostatin receptor-targeted radionuclide therapy. Int J Cancer 2001;92(5):628–33.

    Article  PubMed  Google Scholar 

  25. Valdes Olmos RA, Hoefnagel CA. Radionuclide therapy in oncology: the dawning of its concomitant use with other modalities? Eur J Nucl Med Mol Imaging 2004;31(7):929–31.

    Google Scholar 

  26. Bodei L, Cremonesi M, Zoboli S, Grana C, Bartolomei M, Rocca P, et al. Receptor-mediated radionuclide therapy with 90Y-DOTATOC in association with amino acid infusion: a phase I study. Eur J Nucl Med Mol Imaging 2003;30(2):207–16.

    CAS  PubMed  Google Scholar 

  27. Chung JK, Kang JH. Translational research using the sodium/iodide symporter in imaging and therapy. J Nucl Med Mol Imaging 2004;31:799–802.

    Google Scholar 

Download references

Acknowledgements

It would not have been possible to write this editorial commentary without the assistance of, and stimulating discussions with, Pier Francesco Rambaldi MD, and Vincenzo Cuccurullo MD.

Author information

Authors and Affiliations

  1. Nuclear Medicine, Second University of Naples, Piazza Miraglia 2, 80138, Napoli, Italy

    Luigi Mansi

Authors
  1. Luigi Mansi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Luigi Mansi.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Mansi, L. From the magic bullet to an effective therapy: the peptide experience. Eur J Nucl Med Mol Imaging 31, 1393–1398 (2004). https://doi.org/10.1007/s00259-004-1661-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00259-004-1661-3

Search

Navigation